The effect of citicoline on stroke: A comparative study from the Eastern part of India
Saikat Ghosh, Somak Kumar Das1, Tanusree Nath
1Department of Medicine, College of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India.
Insights
Citicoline treatment significantly improved recovery outcomes in stroke patients within 48 hours of onset. This neuroprotective agent enhanced functional recovery at one and three months, indicating a favorable prognosis.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Citicoline is recognized as a neuroprotective agent.
- It demonstrates significant positive outcomes in acute stroke management.
Purpose of the Study:
- To evaluate the efficacy of citicoline in improving outcomes for patients with acute stroke.
- To compare the recovery rates of stroke patients treated with citicoline versus standard care.
Main Methods:
- A hundred patients with ischemic or hemorrhagic stroke within 48 hours of onset were enrolled.
- Fifty patients received citicoline plus standard stroke management (cases), while 50 received standard care only (controls).
- Patient outcomes were assessed using the National Institute of Health Stroke Scale and Barthel Index (BI) at 1 and 3 months.
Main Results:
- Citicoline treatment group showed significantly higher mean BI scores at 1 and 3 months (P < 0.001 and P = 0.002, respectively).
- A greater percentage of patients in the citicoline group achieved a BI score of 85-100 at 3 months (36% vs. 10% in controls, P < 0.05).
- Subgroup analysis revealed significant improvements in both ischemic and hemorrhagic stroke patients treated with citicoline.
Conclusions:
- Citicoline treatment enhances the likelihood of complete recovery and favorable outcomes in stroke patients presenting within 48 hours.
- The benefits of citicoline were observed across all stroke types and at both 1 and 3-month follow-ups.
Background:
Citicoline is a novel neuroprotective agent used in acute stroke with a significantly favorable outcome.
Materials And Methods:
A hundred patients who suffered from either an ischemic and hemorrhagic stroke and who presented to the hospital within 48 h of stroke onset were enrolled for the study. Of these 100 patients (age- and sex-matched), 50 patients were treated with citicoline along with the standard stroke management and considered as 'cases'. The other 50 patients who were administered the standard stroke treatment were considered as 'controls.' The baseline parameters of the patients was assessed using the National Institute of Health Stroke Scale. The patients were reassessed at follow up at the end of the 1st and 3rd month of the commencement of the therapy and their outcome was evaluated by the Barthel Index score (BI).
Results:
The mean BI scores of all categories at the 1st and 3rd month were significantly higher in the citicoline treatment group (P < 0.001 at the 1st month and P = 0.002 at the 3rd month). An analysis of the categorized BI score showed that there was a significant difference in the number of patients in the categorized BI score (85-100) (at the 1st month follow-up: 0% in control vs. 7% in case group [P < 0.05]; and, at the 3rd month follow-up: 10% in control vs. 36% in citicoline case group [P < 0.05]). In the subgroup analysis, both patients suffering from either ischemic and hemorrhagic stroke (including all categories of BI score) in the citicoline treatment group showed a significantly higher mean BI score at the 1st month (ischemic: P = 0.003, hemorrhagic: P =0.04) and also at the end of the 3rd month (ischemic: P = 0.03, hemorrhagic: P = 0.03). An analysis of the categorized BI score (85-100) at the end of the 3rd month in both the hemorrhagic as well as the ischemic subgroups showed a significant incidence of improvement in the citicoline group compared with the control group (hemorrhagic-- control: 6.66% vs.
Case:
31.81%, P < 0.05 and ischemic-- control: 11.41% vs.
Case:
35.71%, P < 0.05).
Conclusion:
In patients suffering from stroke and presenting within 48 h of onset, treatment with citicholine increases the probability of complete recovery and a favorable outcome at the 1st month and at the end of the 3rd month in all the stroke groups.
